Outcomes Associated with Dronedarone Use in Patients with Atrial Fibrillation.

Area of Science:

• Cardiology
• Pharmacology
• Epidemiology

Background:

• Dronedarone was developed to mitigate amiodarone's adverse effects in atrial fibrillation/atrial flutter (AF/AFL) patients.
• Existing antiarrhythmic drugs (AADs) carry risks, necessitating comparative safety and efficacy studies.

Purpose of the Study:

• To compare the risk of cardiovascular-related hospitalizations and death in AF/AFL patients treated with dronedarone versus other AADs.
• To evaluate dronedarone's safety profile in a real-world epidemiological setting.

Main Methods:

• Retrospective cohort study design.
• Propensity score matching was used to create comparable groups of dronedarone and other AAD users.
• Primary outcome: cardiovascular hospitalization within 24 months. Secondary outcome: composite of cardiovascular hospitalization or all-cause mortality.

Main Results:

• The study included 6,349 dronedarone users and 12,698 other AAD users in the propensity score-matched cohort.
• Dronedarone users exhibited a significantly lower risk of cardiovascular hospitalization (HR=0.87; 95% CI=0.79-0.96).
• A similar significant reduction in risk was observed for the composite outcome of cardiovascular hospitalization or all-cause mortality (HR=0.86; 95% CI=0.78-0.95).

Conclusions:

• Initiating dronedarone in AF/AFL patients is associated with a significantly lower risk of cardiovascular hospitalizations compared to other AADs.
• Dronedarone demonstrates a favorable risk profile regarding cardiovascular events and mortality in AF/AFL management.
• These findings suggest dronedarone as a potentially safer alternative for AF/AFL treatment, warranting further clinical consideration.